BDB101 / Seven and Eight BioPharma, Eikon Therap - LARVOL DELTA

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists (Businesswire) - "Seven and Eight Biopharmaceuticals...announced today that it has signed an exclusive licensing agreement with Eikon Therapeutics. As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8)....The exclusive licensing agreement also includes development of novel Toll-like receptor ligand antibody conjugation (TLAC) molecules."

Licensing / partnership • Oncology • Solid Tumor

Evaluation of BDB101, a first-in-class TLR7/8 dual agonist conjugated to an anti-PD-L1 mAb, in cancer treatment (AACR 2023) - "This allows for delivery and release of higher doses of the TLR agonist in the TME while limiting systemic exposure.BDB001 is an intravenously (IV) delivered TLR7/8 dual agonist that activates both the innate and adaptive immune system. The low rate of free TLR7/8 dual agonist payload released into the systemic circulation from the conjugated form of BDB101, should minimize the risk of systemic TLR7/8 dual agonist exposure, while maintaining the ability to deliver the payload to the TME. These results indicate that BDB101 will likely have a good in vivo therapeutic window and strongly support the clinical development of BDB101."

IO biomarker • Oncology • TLR7 • TLR8